Scottsdale, AZ, United States of America

David Renzi

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Impra, Inc.,. Active years: 2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Renzi. Retrieved from https://idiyas.com/inventor/david-renzi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 259(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: David Renzi: Innovator in Medical Technology

Introduction

David Renzi is an accomplished inventor based in Chandler, AZ. He is currently associated with Bard Peripheral Vascular, Inc., a company known for its advancements in medical technology. Although he has not yet registered any patents, his contributions to the field are noteworthy.

Latest Patents

As of now, David Renzi holds 1 patents. However, his work at Bard Peripheral Vascular, Inc. may lead to future innovations that could significantly impact the medical industry.

Career Highlights

David has built a career focused on developing medical devices that enhance patient care. His role at Bard Peripheral Vascular, Inc. allows him to collaborate with other professionals in the field, contributing to the advancement of vascular health solutions.

Collaborations

One of David's notable coworkers is John D. McDermott. Together, they work on projects that aim to improve medical technologies and patient outcomes.

Conclusion

David Renzi is a promising inventor in the medical technology sector, and his ongoing work at Bard Peripheral Vascular, Inc. may lead to significant innovations in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…